StockTipsArenaBeta

BUY Aurobindo Pharma — Rupak De, LKP Securities

BUYAurobindo Pharma
Aurobindo Pharma share price target & all analyst calls

byRupak De, LKP SecuritiesHorizon: NA (inferred Swing (≤2wk))5 Aug 2026via Business Today

Entry₹1,587.3Inferred
Target₹1,720
Total upside +8.36% (call closed)
Stop loss₹1,570-1.09% risk
Exit₹1,5705 Aug 2026, 9:25 am
Stop-loss hit-1.09%
Follow Rupak De for new calls(16% target hit, 104 closed calls)Get alertsWatch AUROPHARMA for new buy/sell callsGet alertsSee 1 active Swing call on AUROPHARMASee 149 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 5 Aug 2026
6 supporting2 neutral2 opposing
Supports the BUY call (6)

Aurobindo Pharma shares rise 2.01% in today's trade

NewsGoogle News·4 Aug · today

(opens in new tab)

1 advisor has an active intraday BUY call on this stock, issued in the last 14 days

Advisor consensus · adjacent horizon·4 Aug · today

3 other SEBI-registered advisors have active swing BUY calls on this stock, all issued in the last 14 days

Advisor consensus · same horizon·4 Aug · today

Aurobindo Pharma FY26 Results: Revenue up 2.2% to ₹111,717 Cr

NewsGoogle News·3 Aug · yesterday

(opens in new tab)

Aurobindo Pharma has signed a non-exclusive voluntary license agreement with MSD to supply generic alimatravir to 129 Low- & Middle-Income Countries (LMICs). This royalty-free agreement aims to expand

BSE · Company Update·24 Jul · 2w ago

(opens in new tab)
Neutral / worth noting (2)

Aurobindo Pharma signs licensing pact with Merck to supply generic HIV drug in 129 countries

NewsCnbc-Tv18·24 Jul · 2w ago

(opens in new tab)

Aurobindo Pharma arm Apitoria to acquire 80% stake in A1 Biochem Group for $17 million

NewsCnbc-Tv18·23 Jul · 2w ago

(opens in new tab)
Weighs against the BUY call (2)

US tariff threat drags Nifty Pharma 1.4% lower; Lupin, Auropharma lead decline

NewsHbl·22 Jul · 2w ago

(opens in new tab)

Pharma stocks decline; Aurobindo Pharma down over 4%

NewsHbl·22 Jul · 2w ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Aurobindo Pharma

All analyst calls on Aurobindo Pharma

More from Rupak De, LKP Securities

Every call and its outcome